Digital Oral Presentation Session 3 - Vedolizumab and ustekinumab therapies

  • 17:45-18:45 Digital Oral Presentation Session 3 – Vedolizumab and ustekinumab therapies
    Chairs:
    Pieter Hindryckx, Ghent, Belgium
    Laurent Peyrin-Biroulet, Vandeouvre-les-Nancy, France
      17:45-17:51 DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s Disease: A GEMINI 2 post hoc analysis

    Feagan, B.G.
    1, Sandborn, W.J.2, Colombel, J.-F.3, O'Byrne, S.4, Khalid, J.M.5, Brayshaw, N.6, Geransar, P.7, Rubin, D.T.8

    1Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials Inc, London, Canada, 2University of California San Diego, Division of Gastroenterology, La Jolla, United States, 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, 4Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, United Kingdom, 5Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom, 6Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom, 7Takeda Pharmaceuticals International AG, Global Medical Affairs, Zürich, Switzerland, 8University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States
      17:51-17:57 DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn’s Disease and Ulcerative Colitis on maintenance therapy with vedolizumab

    Yarur, A.1, Bruss, A.[1], Jain, A.2, Kondragunta2, V.2, Hester, K.2, Luna, T.2, Agrawal, D.1, Patel, A.1, Fox, C.1, Werner, S.1, Naik, S.2, Stein, D.1

    1Medical College of Wisconsin, Gastroenterology and Hepatology, Milwaukee, United States, 2Prometheus Laboratories, San Diego, United States
      17:57-18:03 DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn’s Disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study

    Vermeire, S.
    1, Loftus, E.V.2, Colombel, J.-F.3, Feagan, B.4, Sandborn, W.5, Sands, B.6, Danese, S.7, D'Haens, G.8, Kaser, A.9, Panaccione, R.10, Rubin, D.11, Shafran, I.12, O'Byrne, S.13, Geransar, P.13, Previtali, A.14, Khalid, J.M.15, Kaviya, A.16

    1University Hospitals Leuven, Dpt of Gastroenterology, Leuven, Belgium, 2Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, United States, 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, 4Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada, 5University of California - San Diego, Division of Gastroenterology, La Jolla, United States, 6Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 7Humanitas University , Italy, Gastrointestinal Immunopathology, Milan, Italy, 8Academic Medical Centre, Dept. of Gastroenterology, Amsterdam, Netherlands, 9University of Cambridge, Division of Gastroenterology and Hepatology, Cambridge, United Kingdom, 10University of Calgary, Department of Medicine, Calgary, Canada, 11University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States, 12Shafran Gastroenterology Research center, Gastroenterology, Winter Park, United States, 13Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland, 14Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom, 15Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom, 16Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom
      18:03-18:09 DOP022: Vedolizumab (VDZ) and anti-TNFa treatment effectiveness in patients with IBD treated in Germany: A retrospective chart review

    Ehehalt, R.
    1, Schubert, S.2, Stein, D.3, Lambrelli, D.4, Bassel, M.5, Orzechowski, H.-D.6, Minda, K.7, Khalid, J.M.8

    1Gastroenterology Outpatient Clinic, Heidelberg, Germany, 2Gastroenterologist in Private Practice, Berlin, Germany, 3Evidera, Montreal, Canada, 4Evidera, Hammersmith, United Kingdom, 5UBC: An Express Scripts Company, Montreal, Canada, 6Takeda Pharma GmbH, Berlin, Germany, 7Takeda Pharmaceuticals International AG, Zurich, Switzerland, 8Takeda Development Centre Europe Ltd, London, United Kingdom
      18:09-18:15 DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active Ulcerative Colitis: Results from the US VICTORY consortium

    Dulai, P.
    1, Meserve, J.1, Hartke, J.2, Chilukuri, P.2, Chaudrey, K.3, L. Koliani-Pace, J.4, Kochhar, G.5, P. Parikh, M.5, Shmidt, E.6, Hirten, R.6, Luo, M.7, Barocas, M.7, Lasch, K.7, Sultan, K.8, Swaminath, A.9, Bohm, M.10, Lukin, D.11, Hudesman, D.12, Shen, B.5, A. Siegel, C.4, E. Sands, B.6, Colombel, J.-F.6, Kane, S.3, V. Loftus Jr, E.3, Singh, S.1, J. Sandborn, W.1, S. Boland, B.1

    1University of California - San Diego, La Jolla, United States, 2Indiana University School of Medicine, Indianapolis, United States, 3Mayo Clinic, Rochester, United States, 4Dartmouth-Hitchcock Medical Center, Lebanon, United States, 5Cleveland Clinic Foundation, Cleveland, United States, 6Icahn School of Medicine at Mount Sinai, New York, United States, 7Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, 8North Shore University Hospital, Manhasset, United States, 9Lenox Hill Hospital, New York, United States, 10Indiana University Hospital, Indianapolis, United States, 11Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States, 12New York University School of Medicine, New York, United States
      18:15-18:21 DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infections

    Ng, S.C.1, Palo, W.2, Blake, A.3, Rana-Khan, Q.4, Jandura, J.4, Bhayat, F.5
    1Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, Hong Kong, 2Takeda Development Center Americas, Inc., Global Statistics and Statistical Programming, Deerfield, United States, 3Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom, 4Takeda Pharrmaceutical International AG Singapore, Emerging Markets Medical Affairs , Singapore, Singapore, 5Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom
       18:21-18:27 DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAID

    Tadbiri, S.1, Grimaud, J.C.2, Peyrin-Biroulet, L.3, Filippi, J.4, Pariente, B.5, Roblin, X.6, Buisson, A.7, Stefanescu, C.8, Trang-Poisson, C.9, Altwegg, R.10, Marteau, P.11, Vaysse, T.12, Bourrier, A.13, Nancey, S.14, Laharie, D.15, Allez, M.16, Bouhnik, Y.8, Amiot, A.17

    1CHU Henri Mondor, Department of Gastroenterology, Creteil, France, 2Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France, 3CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, 4Archet 2 Hospital, Department of Gastroenterology, Nice, France, 5CHRU Lille, Department of Gastroenterology, Lille, France, 6University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, 7CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, 8APHP Beaujon, Department of Gastroenterology, Clichy, France, 9CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, 10CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, 11Hospital Lariboisière, Department of Gastroenterology, Paris, France, 12CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France, 13APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France, 14Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, 15CHU Bordeaux, Department of Gastroenterology, Bordeaux, France, 16Hospital Saint-Louis, Department of Gastroenterology, Paris, France, 17Henri Mondor Hospital, Gastroenterology, Creteil, France
       18:27-18:33 DOP026: Sustained remission with vedolizumab in patients with Moderately to Severely active Ulcerative Colitis: A GEMINI 1 post hoc analysis of Week 14 remitters

    Stallmach, A.
    1, Bokemeyer, B.2, Axler, J.3, Curtis, R.4, Ehehalt, R.5, Feagan, B.6, Geransar, P.7, James, A.8, Kaviya, A.9, Khalid, J.M.10, Wolf, D.11, Schreiber, S.12

    1University hospital Jena, Department of Internal Medicine IV, Jena, Germany, 2Gastroenterology Practice, Private practice, Minden, Germany, 3TDDA (Toronto Digestive Disease Associates Inc.), Toronto, Canada, 4Takeda Development Centre Europe Ltd, Global Medical Affairs, London, United Kingdom, 5Praxis für Gastroenterologie, Gastroenterology, Heidelberg, Germany, 6Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada, 7Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland, 8Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom, 9Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom, 10Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom, 11Atlanta Gastroenterology Associates, Emory Saint Joseph's, Atlanta, United States, 12University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany
       18:33-18:39 DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn’s Disease patients: A multicenter retrospective experience

    Wils, P.1, Bouhnik, Y.2, Michetti , P.3, Flourie , B.4, Brixi , H.5, Bourrier, A.6, Allez, M.7, Duclos , B.8, Serrero, M.9, Buisson, A.10, Amiot, A.11, Fumery , M.12, Roblin, X.13, Peyrin-Biroulet, L.14, Filippi , J.15, Bouguen, G.16, Abitbol , V.17, Coffin , B.18, Simon, M.19, Laharie , D.20, Pariente, B.1

    1University of Lille 2, Department of Gastroenterology, Lille, France, 2Beaujon Hospital, Gastroenterology Unit, Clichy, France, 3University Hospital Lausanne, Division of Gastroenterology & Hepatology,, Lausanne, Switzerland, 4Centre Hospitalier Lyon-Sud, Service d'Hépato-gastro-entérologie, Lyon, France, 5CHU de Reims, Gastroenterologie, Reims, France, 6University Hospital of Saint Antoine, APHP, Gastroenterology, Paris, France, 7APHP, Hopital Saint Louis, Department of Gastroenterology, Paris, France, 8Université de Strasbourg, Gastroenterology, Strasbourg, France, 9Hospital Nord Assistance Publique de Marseille, Department of Gastroenterology, Marseille, France, 10Clermont-Ferrand University, Clermont-Ferrand, France, 11Hospital Henri-Mondor, Department of Gastroenterology, Creteil, France, 12Amiens University Hospital, Gastroenterology, Amiens, France, 13University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, 14CHU Nancy, Department of Gastroenterology, Nancy, France, 15CHU de Nice, Department of Gastroenterology, Nice, France, 16CHU Rennes, Department of HepatoBiliary Surgery and Digestive, Rennes, France, 17Cochin University Hospital, Gastroenterology, Paris, France, 18Hopital Louis-Mourier, Gastroenterologie, Colombes, France, 19Institut Mutualiste Montsouris , Gastroenterology , Paris, France, 20CHU de Bordeaux, Gastroenterology, Pessac, France